eG Innovations Announces Free, SaaS-Based Logon Simulator for VMware Horizon
eG Innovations, a leading IT performance management software provider, announced today the expansion of its free online eG Enterprise Express SaaS solution to help VDI-driven organizations quickly identify and remediate logon issues that negatively affect the user experience and business productivity. eG Enterprise Express Logon Simulator for Citrix and VMware Horizon now provides any VMware Horizon administrator with a no-risk, powerful “synthetic” monitoring tool to track logon performance, whether hosted on premise, in the cloud, or in a hybrid environment.
“Slow logon performance has been one of the most challenging user complaints that VDI administrators and support teams have to deal with,” said Srinivas Ramanathan, chief executive officer, eG Innovations. “When a user logs on to a virtual desktop, there are many interactions that need to occur between different infrastructure elements. A slow-down anywhere in the infrastructure – the VMware Connection Server, the vSphere ESX servers, VMware vCenter, storage, Active Directory, profile servers, etc. – can result in slow logons. VDI administrators must be able to detect such situations proactively and resolve them. 24x7 simulation and alerting on virtual desktop logon failures provides VDI administrators with exactly what they need to proactively detect and fix such issues, and thereby ensure a great user experience”.
With this new release, organizations can now use the eG Enterprise Express free logon simulator to monitor desktop and application virtualization infrastructures running on either VMware Horizon or Citrix XenApp and XenDesktop. eG Enterprise Express allows administrators to continuously simulate the exact same steps that users take to log on to the VMware Horizon environment. Administrators can receive real-time alerts, analyze performance over time and generate SLA reports using a web browser. A mobile app providing on-the-go access is also available. “We’re pleased to offer this capability as a free resource for VMware Horizon admins everywhere, to help make their job easier and improve their users’ experience” said Ramanathan.
This SaaS solution can be set up in minutes and is being offered free of charge forever. A simple website signup is the only requirement to get started.
- Synthetic logon simulation tool for monitoring, diagnosis, alerting and reporting of VMware Horizon logon performance
- Tracks every step of the Horizon logon process (browser access, authentication, enumeration, session establishment, and application launch), and pinpoints which step is causing logon slowdown
- Proactively diagnoses logon issues before users are affected
- Supports logon simulation for both virtualized applications and desktops
- Tests if the entire VMware Horizon delivery infrastructure is working in concert
- Quick SaaS deployment – up and running in minutes
- Web-based monitoring console
- Intuitive dashboards for logon performance monitoring
- 7-day historical reporting allows analyzing performance trends
- Optimized for VMware Horizon 7.x environments
The eG Enterprise Express Free Logon Simulator for Citrix and VMware Horizon is available now. Register on the eG Innovations website to get started now.
On-site at VMworld 2017 Europe in Barcelona: Get a live demo of eG Enterprise Express in booth #E526, and register to win a Google Home.
About eG Innovations
eG Innovations is dedicated to helping businesses across the globe transform IT service delivery into a competitive advantage and a center for productivity, growth and profit. Many of the world's largest businesses use eG Enterprise to enhance IT service performance, increase operational efficiency, ensure IT effectiveness and deliver on the ROI promise of transformational IT investments across physical, virtual and cloud environments. Visit us at www.eginnovations.com or on Twitter at @eGInnovations.
All trademarks, service marks and company names are the property of their respective owners.
For eG Innovations
Erin Farrell Talbot, 917-232-9309
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Shell, bio-bean and Coffee-Drinkers Collaborate to Help Power London’s Buses20.11.2017 00:01 | Pressemelding
Shell and bio-bean announce that together they are helping to power some of London’s buses using a biofuel made partly from waste coffee grounds. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171119005060/en/ Shell and bio-bean announce that together they are helping to power some of London's buses using a biofuel made partly from waste coffee grounds (Photo: Business Wire) The B20 biofuel contains a 20% bio-component which contains part coffee oil. The biofuel is being added to the London bus fuel supply chain and will help to power some of the buses; without need for modification. Biofuel provides a cleaner, more sustainable energy solution for buses across London’s network by decreasing emissions1. “Our Coffee Logs have already become the fuel of choice for households looking for a
Samsung Bioepis Receives Regulatory Approval for Europe's First Trastuzumab Biosimilar, ONTRUZANT®19.11.2017 22:21 | Pressemelding
Samsung Bioepis Co., Ltd. today announced the European Commission’s (EC) marketing authorization of ONTRUZANT ® , a biosimilar referencing Herceptin ® (trastuzumab), for the treatment of early breast cancer, metastatic breast cancer and metastatic gastric cancer. ONTRUZANT ® is the first trastuzumab biosimilar to receive regulatory approval in Europe. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171119005066/en/ Christopher Hansung Ko, President & CEO of Samsung Bioepis. (Photo: Business Wire) The EC approval of ONTRUZANT ® applies to all 28 European Union (EU) member states and the European Economic Area (EEA) member states of Norway, Iceland and Liechtenstein. ONTRUZANT ® will be commercial
Cancer Patients, Survivors, Supporters and Caregivers Undertake UAE's First Relay for Life19.11.2017 16:31 | Pressemelding
Sharjah, the third largest of the United Arab Emirate’s seven emirates, was the host for the MENA region’s first ever ‘Global Relay for Life,’ (RFL) a 24-hour walkathon that is the biggest fundraising event for cancer in the world. Conducted in conjunction with the American Cancer Society, the event was organised by Friends of Cancer Patients (FoCP), a non-profit organisation that supports cancer patients and their families. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171119005048/en/ During MENA's first Global Relay For Life walkathon - Source: Friends of Cancer Patients Taking place November 17-18 at the American University Sharjah, the inaugural UAE RFL saw more than 2,000 relayers participating in the overnight event, with a large number of individuals and institutions involved including 52 sch
New Data Show Benefit of Tagrisso in Patients with EGFR-mutated Non-small Cell Lung Cancer and Central Nervous System Metastases18.11.2017 23:00 | Pressemelding
AstraZeneca today presented new data from a subgroup analysis of the Phase III FLAURA trial, which explored osimertinib as 1st-line therapy in patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). Results presented at the ESMO Asia 2017 Congress in Singapore showed that patients with central nervous system (CNS) metastases at baseline had a higher objective response rate with their brain metastasis and suggest a lower risk of CNS progression when treated with osimertinib, a third-generation, irreversible EGFR tyrosine kinase inhibitor (TKI), versus current standard-of-care EGFR-TKIs (erlotinib or gefitinib) [Abstract LBA5].1 The analysis included patients with ≥1 measurable and/or non-measurable CNS lesion present on baseline scan (as assessed by blinded independent central review), accounting for 23
New England Journal of Medicine Publishes Results of Phase III FLAURA Trial in the 1st-Line Treatment of EGFR-mutated Non-small Cell Lung Cancer18.11.2017 18:20 | Pressemelding
AstraZeneca today announced that the New England Journal of Medicine has published the positive results from the Phase III FLAURA trial which provide data for Tagrisso’s (osimertinib) use in the 1st-line treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC).1 The trial showed a statistically significant, clinically meaningful progression-free survival (PFS) advantage for osimertinib, a third-generation, irreversible EGFR tyrosine kinase inhibitor (TKI), compared with current 1st-line EGFR-TKIs, erlotinib or gefitinib.1 This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171118005044/en/ Dr. Suresh S. Ramalingam, Principal Investigator of the FLAURA trial, from the Winship Cancer Institute
Much-Anticipated CHTF 2017 Top 10 Products Are Unveiled18.11.2017 09:11 | Pressemelding
The 19th China Hi-Tech Fair (CHTF 2017), with the theme of “Innovation-Driven Development and Supply Quality Upgrade”, is taking place from November 16 to 21 at Shenzhen Convention and Exhibition Center. On the afternoon of November 10, the CHTF 2017 Top 10 Products were unveiled at the awards ceremony by Mr. Gao Zimin, Vice Mayor of Shenzhen City. A total of 322 entries competed for the honor Top 10 Products, and the voting lasted nearly 3 months. 60 candidate products in the fields of new energy, 3D print, flexible display, life sciences, unmanned vehicles and AI were shortlisted by the organizer, experts and media representatives and went for open voting online. The final Top 10 Products all represent the most advanced technologies in their respective sectors: the water-making device that can make water out of air, the smart sportswear that can monitor heartbeat and other
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom